Taras Mahlay
Internal Medicine · North Royalton, OHNPI 1285727164
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 110 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,295 and has fallen 98.9% since, to $15 in 2022.
Across 110 payments — averaging $15.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$228
- Sanofi-aventis U.S. LLC$199
- AstraZeneca$169
- Lilly USA, LLC$162
- Amgen$162
- AbbVie$133
- plus $631 from 17 others
What the payments were for
- Food & beverage$1,674100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 13 | $228 |
| Sanofi-aventis U.S. LLC | 12 | $199 |
| AstraZeneca | 13 | $169 |
| Lilly USA, LLC | 14 | $162 |
| Amgen(2 entities) | 10 | $162 |
| AbbVie | 7 | $133 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $90 |
| Pfizer | 5 | $76 |
| Amarin Pharma, Inc. | 5 | $73 |
| Abbott | 4 | $70 |
| Johnson & Johnson | 4 | $56 |
| Mannkind Corporation | 3 | $54 |
| Boehringer Ingelheim | 3 | $39 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Merck | 2 | $25 |
| Shire North American Group Inc | 1 | $23 |
| Radius Health, Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Valeritas, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| IBSA Pharma Inc. | 1 | $13 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
How this compares
$1,682 in reported general payments places this provider in the 80th percentile of 4,428 internal medicine providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 16 | $5,969 |
| Finasteride | 15 | $371 |
| Omeprazole | 15 | $363 |
| Doxazosin Mesylate | 15 | $323 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in North Royalton
- Hassan MalikAkron$1.7M
- Cyrus HarrisCleveland$726K
- Nina DeepWesterville$614K
- Necklall KhooblallAustintown$448K
- Daniel WeissMentor$406K
- Richard KimDayton$326K
- Marina MagreyCleveland$312K
- Lisa LarkinCincinnati$276K
- Gregg FaimanMayfield Hts$274K
- Vincent MartinCincinnati$261K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.